According to the ANSM, the use of hydroxychloroquine by Professor Raoult to treat Covid patients “should have received a favorable opinion from a committee for the protection of persons and authorization.” A panel of doctors recently called this protocol “the largest wild therapeutic trial known.”
Article written by
Published
Update
Reading time : 1 min.
/2023/06/03/647b2fea9801b_000-328l8vp.jpg)
The National Medicines Safety Agency (ANSM) announces that it “prepares to take legal action“concerning the publication of a study”pre print“controversial co-signed by Didier Raoult, learned franceinfo Saturday June 3 from the ANSM.
>>> Covid-19: infectious disease specialist Didier Raoult denies having carried out a “therapeutic trial”
The former director of the Marseille IHU published a study in March on the supposed effectiveness of treatments such as hydroxychloroquine. This is a “pre print“, that is, a non-peer-reviewed version, of his study of over 30,000 Covid patients.”After analysis, we confirm that this study can be qualified as category 1 RIPH“, indicates the ANSM. “This study should therefore have received a favorable opinion from a committee for the protection of persons (CPP) and authorization from the ANSM to be implemented.“, she adds.
This publication had been described earlier this week as “largest known ‘wild’ therapeutic trial“by 16 learned medical societies in a column published in the daily Le Monde.
View comments